Pulsed dye laser and topical timolol gel versus pulse dye laser in treatment of infantile hemangioma: A double-blind randomized controlled trial

Abstract

BACKGROUND: Infantile hemangioma (IH) is the most common tumor during infancy that usually appears as macular and gradually becomes a plaque or tumor. Approximately, 20 of all IH cases results in adverse effects and the Pulsed dye laser (PDL) 585 nm is a vascular laser leading to selective the micro vascular damage. Results of studies on non-selective B-blockers (e.g., timolol) indicate their effectiveness in preventing hemangioma growth. The aim of this study is a comparison of PDL plus timolol and PDL in the treatment of IH. MATERIALS AND METHODS: This double-blind study was carried out on 30 infants (1-12 months old) and the patients were divided into two groups. Group A was treated with the four sessions PDL and the timolol gel 0.05 and Group B with PDL. RESULTS: There were no differences in the mean age of patients for the diagnosis of hemangioma (Group A: 32.69 +/- 24.64 days, Group B: 25.69 +/- 21.16 days, P = 0.39) and the mean age at the start of the treatment (Group A: 148.125 +/- 85.88 days, Group B: 146.25 +/- 60.87 days, P = 0.94). There were a statistical difference in the mean of lesion size reduction (Group A: 17.62 +/- 6.97 cm and Group B: 12 +/- 5.71 cm, P = 0.018), mean percentage change in size mean (Group A: 71079 +/- 23.41 and Group B: 54.59 +/- 25.46, P = 0.050) visual analog scale (Group A: 7.19 +/- 1.51, Group B: 5.62 +/- 1.78, P = 0.012) after treatment. There was no correlation between the time of beginning the treatment and the results (P = 0.857). CONCLUSIONS: Application of timolol with PDL is accompanied by the highest efficacy, cost benefits and the short time of treatment.